Pulmonology & Thoracic Medicine

COPD

Triple inhaler therapy optimization, bronchoscopic lung volume reduction (Zephyr valves), and pulmonary rehab.

Treatment Options

Recommended Centers

$14,000

Starting From

7-21 days

Typical Wait

Treatment Plans for COPD

Compare evidence-based options at top Chinese hospitals — transparent pricing, typical wait, and recovery time.

Flagship Plan

Bronchoscopic Lung Volume Reduction (Zephyr)

Endobronchial valve placement for severe emphysema with hyperinflation.

Wait Time

14-21 days

Hospital Stay

5-7 days

Recovery

4-6 weeks

Estimated Price

Approx. $18,000

View Detailed Introduction — Procedure, Price Comparison & More

Price Comparison: China vs. USA

🇨🇳 China

$14,000

🇺🇸 USA

$62,500+

Save up to $48,500 per treatment

Procedure Steps

Pre-op: HRCT chest + perfusion scan + 6MWT + fissure integrity assessment (Chartis)

Conscious sedation + local anesthetic spray to airway

Flexible bronchoscopy with target lobe identification

Chartis catheter assessment of collateral ventilation (CV-)

Sequential Zephyr valve deployment (3-5 valves per lobe)

Post-procedure observation for pneumothorax (highest risk Day 1-3)

Discharge Day 3-5 with chest X-ray monitoring

Pulmonary rehabilitation 6 weeks post-procedure

What are Zephyr Endobronchial Valves?

One-way valves placed bronchoscopically into the most diseased lobe of an emphysema lung, blocking inhaled air while allowing trapped air to escape. The hyperinflated lobe deflates, allowing healthier lobes to expand — essentially a non-surgical lung volume reduction.

Why China?

Cost: $25,000-$38,000 vs. $50,000-$90,000 in the US
NMPA approved: Pulmonx Zephyr valves available at top respiratory centers
No surgery: Bronchoscopic procedure, 3-5 day hospital stay
Reversible: Valves can be removed if needed

Who is a candidate?

Severe emphysema with hyperinflation (RV ≥175%, FEV1 15-50%)
Heterogeneous emphysema distribution
Intact interlobar fissures (CV-negative on Chartis)
Optimized medical therapy + pulmonary rehab

Outcomes

FEV1 improvement: 18-25%. 6MWT improvement: 30-40m. SGRQ quality of life improvement: clinically significant in 60-70%. Pneumothorax: 25-35% (most resolved with chest tube).

Book Free Consultation WhatsApp

Prices are indicative ranges in USD based on partner hospital published rates. Final quote depends on your medical records and selected hospital — request a free personalized estimate.